BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 26067141)

  • 1. Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome.
    Nguyen TT; Frater JL; Klein J; Chen L; Bartlett NL; Foyil KV; Kreisel FH
    Appl Immunohistochem Mol Morphol; 2016 Jul; 24(6):383-91. PubMed ID: 26067141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival.
    Muenst S; Hoeller S; Dirnhofer S; Tzankov A
    Hum Pathol; 2009 Dec; 40(12):1715-22. PubMed ID: 19695683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell transcription factors Pax-5, Oct-2, BOB.1, Bcl-6, and MUM1 are useful markers for the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma.
    Herbeck R; Teodorescu Brînzeu D; Giubelan M; Lazăr E; Dema A; Ioniţă H
    Rom J Morphol Embryol; 2011; 52(1):69-74. PubMed ID: 21424034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma.
    O'Malley DP; Dogan A; Fedoriw Y; Medeiros LJ; Ok CY; Salama ME
    Ann Diagn Pathol; 2019 Apr; 39():105-110. PubMed ID: 30802809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TiA1 in advanced-stage classical Hodgkin's lymphoma: no prognostic impact for positive tumour cells or number of cytotoxic cells.
    Camilleri-Broët S; Fermé C; Berger F; Lepage E; Bain S; Brière J; Marmey B; Gaulard P; Audouin J
    Virchows Arch; 2004 Oct; 445(4):344-6. PubMed ID: 15221373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis.
    Hsi ED; Sup SJ; Alemany C; Tso E; Skacel M; Elson P; Alonso MA; Pohlman B
    Am J Clin Pathol; 2006 May; 125(5):776-82. PubMed ID: 16707382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact.
    Barros MH; Hassan R; Niedobitek G
    Clin Cancer Res; 2012 Jul; 18(14):3762-71. PubMed ID: 22645050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases.
    Tzankov A; Krugmann J; Fend F; Fischhofer M; Greil R; Dirnhofer S
    Clin Cancer Res; 2003 Apr; 9(4):1381-6. PubMed ID: 12684408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classical Hodgkin lymphoma, lymphocyte depleted type: clinicopathological analysis and prognostic comparison with other types of classical Hodgkin lymphoma.
    Karube K; Niino D; Kimura Y; Ohshima K
    Pathol Res Pract; 2013 Apr; 209(4):201-7. PubMed ID: 23478005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Macrophage, mast cell and T lymphocyte infiltrations are independent predictive biomarkers of primary refractoriness or early relapse in classical Hodgkin lymphoma.
    Deau B; Bachy E; Ribrag V; Delarue R; Rubio MT; Bosq J; Varet B; Brousse N; Hermine O; Canioni D
    Leuk Lymphoma; 2013 Jan; 54(1):41-5. PubMed ID: 22667341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
    Menter T; Bodmer-Haecki A; Dirnhofer S; Tzankov A
    Hum Pathol; 2016 Aug; 54():17-24. PubMed ID: 27045512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-associated mast cells in classical Hodgkin's lymphoma: correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome.
    Andersen MD; Kamper P; Nielsen PS; Bendix K; Riber-Hansen R; Steiniche T; Hamilton-Dutoit S; Clausen M; d'Amore F
    Eur J Haematol; 2016 Mar; 96(3):252-9. PubMed ID: 25963595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of an expanded immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators.
    Cho RJ; McCalmont TH; Ai WZ; Fox LP; Treseler P; Pincus LB
    J Cutan Pathol; 2012 Jun; 39(6):651-8. PubMed ID: 22324490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.
    Rodig SJ; Ouyang J; Juszczynski P; Currie T; Law K; Neuberg DS; Rabinovich GA; Shipp MA; Kutok JL
    Clin Cancer Res; 2008 Jun; 14(11):3338-44. PubMed ID: 18519761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B cells in classical Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction.
    Tudor CS; Distel LV; Eckhardt J; Hartmann A; Niedobitek G; Buettner M
    Hum Pathol; 2013 Nov; 44(11):2475-86. PubMed ID: 24029709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood CD4/CD19 cell ratio is an independent prognostic factor in classical Hodgkin lymphoma.
    Gaudio F; Perrone T; Mestice A; Curci P; Giordano A; Delia M; Pastore D; Specchia G
    Leuk Lymphoma; 2014 Jul; 55(7):1596-601. PubMed ID: 24164533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma.
    Hasselblom S; Sigurdadottir M; Hansson U; Nilsson-Ehle H; Ridell B; Andersson PO
    Br J Haematol; 2007 May; 137(4):364-73. PubMed ID: 17456059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Sirt1 and FoxP3 in classical Hodgkin lymphoma and tumor infiltrating lymphocytes: Implications for immune dysregulation, prognosis and potential therapeutic targeting.
    Quesada AE; Assylbekova B; Jabcuga CE; Zhang R; Covinsky M; Rios A; Nguyen ND; Brown RE
    Int J Clin Exp Pathol; 2015; 8(10):13241-8. PubMed ID: 26722524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma.
    Klein JL; Nguyen TT; Bien-Willner GA; Chen L; Foyil KV; Bartlett NL; Duncavage EJ; Hassan A; Frater JL; Kreisel F
    Am J Clin Pathol; 2014 Mar; 141(3):381-7. PubMed ID: 24515766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of PAX-5 in B Cell Hodgkin and Non Hodgkin Lymphoma.
    Khan MR; Ahmad A; Kayani N; Minhas K
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3463-3466. PubMed ID: 30583670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.